BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Asthma clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for asthma: 145 (72 sponsors; 29 newly posted in the last 180 days, 10 stopped in the last 180 days; 10 new-entrant sponsors). Momentum score 19, rank 31 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 14, Phase 2 39, Phase 3 43, Phase 4 6, N/A 43.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN30P3 8, NA 19, P2 2, P4 134
GlaxoSmithKline12P3 7, P4 2, P1 2, P2 155
Inmunotek S.L.7P3 721
Chiesi Farmaceutici S.p.A.5P2 1, P4 1, P1 1, P3 230
Guangdong Hengrui Pharmaceutical Co., Ltd5P3 2, P2 2, P1 111
Novartis Pharmaceuticals NVS5P3 2, NA 2, P2 102
Pfizer PFE4P1 1, P3 2, P2 132
Generate Biomedicines GENB3P1 1, P3 201
Sanofi SNY5P2 2, NA 1, P4 1, P3 101
Shanghai Mabgeek Biotech.Co.Ltd2P2 1, P3 100
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM2P2 1, P3 102
Areteia Therapeutics1P3 100
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.1P3 100
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1P3 100
Daewon Pharmaceutical Co., Ltd.1P3 100
Lunan Better Pharmaceutical Co., LTD. new entrant1P3 110
Qilu Pharmaceutical Co., Ltd.1P3 100
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.1P3 100
Teva Branded Pharmaceutical Products R&D LLC1P3 101
Amgen AMGN2P1 212
Anhui Palo Alto Pharmaceuticals, Inc.2P2 200
Chiesi Hungary Ltd.2NA 200
Kymera Therapeutics, Inc. KYMR2P2 210
Acurable Ltd.1NA 100
Adhera Health, Inc. new entrant1NA 110

New-entrant sponsors: Lunan Better Pharmaceutical Co., LTD., Adhera Health, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P2Incyte Corporation INCYNCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaModerate to Severe Asthmaactive not recruiting247
2026-12 est.P3Inmunotek S.L.NCT04435990 Efficacy and Safety Evaluation for the Treatment of Allergy Against MitesRhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergicrecruiting150
2026-12 est.P2Enveda TherapeuticsNCT07301255 ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in AdultsAsthmarecruiting50
2026-12 est.P2Connect Biopharm LLC CNTBNCT07705737 Rademikibart IV for Acute Asthma and COPD ExacerbationAsthma Acute; COPD Exacerbation Acuterecruiting40
2026-12-23 est.P3AstraZeneca AZNNCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of BenralizumAsthmaactive not recruiting94
2026-12-27 est.P2AkesoNCT07436221 A Study to Evaluate the Efficacy and Safety of AK139 in Participants With AsthmaAsthmanot yet recruiting160
2026-12-28 est.P3GlaxoSmithKlineNCT07645248 A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)Asthmarecruiting110
2026-12-31 est.P3Teva Branded Pharmaceutical Products R&D LLCNCT06052267 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsAsthmaactive not recruiting2769
2027-01-26 est.P3GlaxoSmithKlineNCT05757102 A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaAsthmaactive not recruiting138
2027-02 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06323213 Efficacy and Safety Study of 610 in Patients With Severe AsthmaAsthmarecruiting480
2027-02 est.P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06680947 A Phase IIb Study of 610 in Participants With Severe Eosinophilic AsthmaAsthmaactive not recruiting225
2027-02 est.P1/P2RIGImmune Inc.NCT07488897 RIG 101 Trial in Healthy Adults and Adults With AsthmaHealthy Adult Participants; Asthma Exacerbation; Safety and Efficacyrecruiting82

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-26P3Teva Branded Pharmaceutical Products R&D LLCNCT06664619 A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years andAsthmacompleted649
2026-10-01 est.P1/P2Prana Therapies IncNCT07245368 Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate AsthmaMild to Moderate Asthmarecruiting96
2026-10 est.P2Advagene Biopharma Co. Ltd.NCT07250594 A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaEosinophilic Asthmanot yet recruiting126
2026-10 est.P3Inmunotek S.L.NCT04898283 Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergicrecruiting180
2026-09-22P2Sanofi SNYNCT06033833 Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of PrevAsthmaterminated335
2026-09-21P3AstraZeneca AZNNCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated Eosinophilic Asthmacompleted130
2026-09-01P2Ethris GmbHNCT07059767 Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus ChallengeAsthma (Diagnosis)completed50
2026-08-31 est.P3Daewon Pharmaceutical Co., Ltd.NCT07168473 Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With AsthmaPerennial Allergic Rhinitis Accompanied by Asthmarecruiting274
2026-08-03P2Shanghai Xin Huanghe Pharmaceutical Co., Ltd.NCT07807007 Efficacy and Safety of CP006 Inhalation Powder in Participants With AsthmaAsthmacompleted150
2026-07-17P2Connect Biopharm LLC CNTBNCT06940141 Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)Asthma Acutecompleted160
2026-07-14P2GlaxoSmithKlineNCT06748053 A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaAsthmaactive not recruiting307
2026-07-06P2Uniquity One (UNI)NCT06496607 A Study to Evaluate Solriktug in Adult Participants With AsthmaAsthmacompleted145
2026-06-01 est.P2/P3Inmunotek S.L.NCT05641272 Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractAllergic Rhinitis; Allergic Asthma; Allergic Rhinoconjunctivitis; Allergy to House Dust Mitenot yet recruiting90
2026-05-26 est.P2Shanghai Mabgeek Biotech.Co.LtdNCT07054034 Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma SubjectsBronchial Asthmaactive not recruiting160

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "asthma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.